Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it
will webcast its corporate presentation at two upcoming investment
conferences in New York City:
-
Mr. Cary J. Claiborne, CFO of Sucampo, will present at the 15th Annual
BIO CEO & Investor Conference on Tuesday, February 12 at 1:00 pm
Eastern.
-
Mr. Claiborne will also host a fireside chat at the Leerink Swann
Global Healthcare Conference 2013 on Thursday, February 14 at 1:30 pm
Eastern.
The presentations will be webcast live and may be accessed from the
Event Calendar page of Sucampo’s website at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar.
Presentation slides will be available via the webcast links. A replay of
both webcasts will also be available on the Company’s website for
several days after the live events. To ensure a timely connection, it is
recommended that users register at least 15 minutes prior to the
scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused
on innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of
prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D.,
Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer,
and co-founder. Prostones, naturally occurring fatty acid metabolites
that have emerged as promising compounds with unique physiological
activities, can be targeted for the treatment of unmet or underserved
medical needs. For more information, please visit www.sucampo.com.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
future financial and operating results, and other statements that are
not historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and health
care legislation; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents and
other protections for innovative products; the risk of new and changing
regulation and health policies in the US and internationally and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise. Forward-looking statements
in this presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in Sucampo's
most recent Form 8-K and 10-K, which the Company incorporates by
reference.
